Skip to main content
Premium Trial:

Request an Annual Quote

Oxagen CEO is Now Affymetrix s Chief Commercial Officer

NEW YORK, July 24 - Affymetrix has hired Trevor Nicholls to be its first chief commercial officer of global operations, said Affymetrix president, Susan Siegel.

Nicholls, who will be responsible for leading Affy's global sales, marketing, and manufacturing operations, was founder and CEO of Oxagen Limited, a UK-based clinical genomics company. He was replaced at Oxagen earlier this month by Mark Payton, former VP of gene and target portfolio, genetics research at GlaxoSmithKline. When Oxagen announced Payton's appointment on July 10, it said that Nicholls would remain in the CEO post "for some months in order to effect a smooth handover."

 

Before founding Oxagen, Nicholls served as the commercial director of the life science business of Amersham International.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.